Premphase 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Premphase 28 Day Availability in 2026

If your patients have been reporting difficulty filling Premphase 28 Day prescriptions, this briefing provides the current landscape on availability, prescribing implications, and practical tools to help maintain continuity of care.

Premphase 28 Day (Conjugated Estrogens 0.625 mg / Medroxyprogesterone Acetate 5 mg, sequential 28-day kit) remains an FDA-approved option for postmenopausal hormone therapy in women with an intact uterus. However, its availability at retail pharmacies has become increasingly inconsistent, creating challenges for both providers and patients.

Background and Timeline

Premphase was first approved by the FDA in 1995 and has been manufactured by Pfizer (originally Wyeth) throughout its history. The medication offers a sequential dosing regimen — 14 days of estrogen-only therapy followed by 14 days of combined estrogen/progestin therapy — designed to more closely mimic the natural hormonal cycle.

Over the past decade, prescribing patterns have shifted significantly toward continuous combined regimens (e.g., Prempro, generic CE/MPA combinations) and newer HRT formulations. This trend has reduced the number of Premphase prescriptions being filled nationally, leading to inventory reduction at many retail pharmacy chains.

Key timeline points:

• 1995: FDA approval of Premphase
• 2002: Women's Health Initiative (WHI) results published, leading to significant decline in all HRT prescriptions
• 2010s: Gradual re-acceptance of HRT for appropriate patients; prescribing shifted toward lower-dose and continuous regimens
• 2023–2025: Continued market consolidation around generic continuous CE/MPA products and bioidentical options
• 2026: Premphase remains available but inconsistently stocked at retail pharmacies

Prescribing Implications

The limited retail availability of Premphase 28 Day has several practical implications for prescribers:

Patient Adherence Concerns

When patients cannot readily fill their prescriptions, adherence suffers. Gaps in HRT can lead to return of vasomotor symptoms, disruption of bone protection, and patient frustration. Consider proactive discussions about availability when initiating or continuing Premphase therapy.

Prior Authorization and Formulary Status

Many insurance formularies have moved Premphase to non-preferred or specialty tiers, requiring prior authorization. Some plans may require step therapy — documentation that the patient has tried and failed on a generic continuous CE/MPA product before covering brand-name Premphase. Be prepared to provide clinical justification for why sequential dosing is necessary for specific patients.

Sequential vs. Continuous Dosing Considerations

While most patients can be effectively managed on continuous combined HRT, some patients specifically benefit from sequential dosing:

• Patients who experience breakthrough bleeding on continuous regimens
• Patients in early menopause or perimenopause who prefer a cycle-like pattern
• Patients who have tolerated sequential dosing well and resist changing their established regimen

For these patients, maintaining access to Premphase — or replicating its dosing schedule with separate components — is clinically important.

Current Availability Picture

As of early 2026, Premphase 28 Day is not listed on the FDA or ASHP drug shortage databases. Pfizer continues to manufacture the product. The availability challenges are primarily driven by:

• Pharmacy-level inventory decisions based on local demand
• No direct generic equivalent of the phased kit
• Limited distributor allocation to low-volume locations

Availability is generally better at:

• Independent pharmacies with flexible ordering
• Mail-order and specialty pharmacies
• Pharmacies affiliated with large health systems

Cost and Access Considerations

Understanding the cost landscape helps inform prescribing decisions and patient counseling:

• Brand Premphase retail price: $280–$320 per 28-day supply
• With discount card: Approximately $230 per supply
• Separate generic components: Generic CE (approx. $15–$30/month) + generic MPA (approx. $10–$20/month) = $25–$50 total
• Generic Prempro (continuous): $99–$240 per 28-day supply with discount card

For patients facing financial barriers, Pfizer RxPathways (pfizerrxpathways.com) offers patient assistance programs that may provide Premphase at no cost to eligible patients.

Tools and Resources for Your Practice

Several tools can help streamline the process of ensuring your patients get their medication:

Medfinder for Providers

Medfinder for Providers allows you and your staff to quickly check which pharmacies near your patient have Premphase 28 Day in stock. This can be integrated into your prescribing workflow to avoid sending patients to pharmacies that don't carry the medication.

Prescribing Alternatives Proactively

Consider including a backup plan on the prescription itself or in your patient instructions. For example:

• Primary: Premphase 28 Day kit
• Alternative: If unavailable, dispense Conjugated Estrogens 0.625 mg daily (days 1–28) + Medroxyprogesterone Acetate 5 mg daily (days 15–28)

This approach ensures the patient has a fallback without needing to schedule another appointment or call your office.

Patient Education Resources

Direct your patients to these resources:

• Premphase 28 Day shortage update for patients
• How to find Premphase 28 Day in stock
• How to save money on Premphase 28 Day

Looking Ahead

The hormone replacement therapy market continues to evolve. Key trends to watch in 2026 and beyond:

• Bioidentical HRT adoption: Products like Bijuva (Estradiol/Progesterone capsule) are gaining traction as alternatives to conjugated estrogen-based products
• Non-hormonal options: Veozah (Fezolinetant), a neurokinin-3 receptor antagonist, provides a non-hormonal option for vasomotor symptoms in patients who cannot take estrogen
• Compounding pharmacy growth: More patients are seeking custom-compounded bioidentical hormones, though quality and consistency remain concerns
• Potential for generic Premphase: No ANDA for a generic Premphase kit has been approved to date, but this remains a possibility in the future

Final Thoughts

Premphase 28 Day remains a valid therapeutic option for postmenopausal women who benefit from sequential HRT dosing. While it is not in formal shortage, the practical challenges of finding it at retail pharmacies require proactive management by prescribers.

Using tools like Medfinder for Providers, documenting clinical rationale for sequential dosing, and equipping patients with backup plans can help ensure continuity of care even when the brand-name product is difficult to locate.

For additional provider resources on managing HRT availability challenges, visit medfinder.com/providers.